SNY - Sanofi

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.81 (-1.61%)
At close: 4:00PM EST

49.67 +0.27 (0.55%)
After hours: 5:17PM EST

Stock chart is not supported by your current browser
Previous Close50.21
Bid49.43 x 1200
Ask49.44 x 2200
Day's Range49.22 - 49.81
52 Week Range40.00 - 51.84
Avg. Volume1,820,933
Market Cap124.914B
Beta (5Y Monthly)0.49
PE Ratio (TTM)25.46
Earnings DateN/A
Forward Dividend & Yield1.74 (3.46%)
Ex-Dividend DateMay 06, 2019
1y Target EstN/A
Press Releases
  • PR Newswire

    Sanofi Wins Prestigious Drug Discovery Award for Innovative Rare Blood Clotting Disorder Treatment[1]

    Sanofi's Cablivi® (caplacizumab), the first nanobody therapy for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP), has been awarded the British Pharmacological Society's Drug Discovery of the Year 2020 award, at last night's annual Pharmacology conference.

  • PR Newswire

    Sanofi awarded $226 million by US government to expand pandemic influenza preparedness

    Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services (HHS) to increase the company's domestic pandemic influenza vaccine production capabilities based in Swiftwater, Pennsylvania.

  • Business Wire

    Consumers File Class-Action Lawsuit Against Makers of Zantac, According to Consumer-Rights Law Firm FeganScott

    Two consumers filed a class-action lawsuit claiming pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi (SNY), among others, failed to warn consumers that the heartburn medication, Zantac, produces a clinically proven carcinogen in the body at levels far beyond what regulators consider safe. According to Beth Fegan, founder and managing member of consumer-rights law firm FeganScott, Zantac and its generic active ingredient, ranitidine, became one of the world’s best-selling drugs through a massive advertising campaign that touted the drug as safe.

  • PR Newswire

    Pivotal data from Phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session

    - CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells. There are currently no approved treatments. CAMBRIDGE, Mass., Nov. 21, 2019 /PRNewswire/ -- Full data from the pivotal Phase 3 CARDINAL trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) with a history of recent transfusions will be presented as part of the Late-Breaking Abstracts Session at the upcoming 61st Annual Meeting of the American Society of Hematology (ASH), December 10 at 7:45AM (ET).

  • PR Newswire

    New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

    *Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma *Rare Blood Disorders: New data spanning extensive portfolio demonstrates scientific ...

  • PR Newswire

    FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

    PARIS, Nov. 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadrivalent contains an additional influenza B strain.

  • PR Newswire

    Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

    "We know that living with type 1 diabetes means dealing with highs and lows in blood sugar, which are worrying and present substantial challenges for young people," said Prof. Dr. Thomas Danne, Director of the Department of General Pediatrics and Endocrinology/Diabetology at the Children's Hospital On the Bult, Hannover Medical School, Germany. The trial, EDITION JUNIOR, is the first randomized, controlled trial comparing Toujeo vs Gla-100 in this group of patients.

  • Sanofi Q3 well on track
    PR Newswire

    Sanofi Q3 well on track

    PARIS , Oct. 31, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN)  Q3 2019 Change Change at CER 9M 2019 Change Change at CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS ...

  • Sanofi to conduct precautionary voluntary recall of Zantac OTC in U.S. and Canada
    PR Newswire

    Sanofi to conduct precautionary voluntary recall of Zantac OTC in U.S. and Canada

    BRIDGEWATER, N.J., Oct. 18, 2019 /PRNewswire/ -- As a precautionary measure, Sanofi will conduct a voluntary recall of Zantac OTC (over-the-counter) in the U.S. and Canada. This recall is being taken due to possible contamination with a nitrosamine impurity called N-nitrosodimethylamine (NDMA). On September 13, 2019, the U.S Food and Drug Administration and Health Canada issued public statements alerting that some ranitidine medicines, including Zantac OTC, could contain NDMA at low levels and asked manufacturers to conduct testing.

  • PR Newswire

    Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

    PARIS, Oct. 15, 2019 /PRNewswire/ -- Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using intensified, continuous biologics production technology. The new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialization of important new medicines for patients. This facility accelerates the recent transformation of Sanofi's Industrial Affairs organization to focus on biologics-based therapies, in line with the transformation of the company's R&D pipeline.

  • Business Wire

    Hagens Berman: Law Firm Taking on Drug Makers in Zantac Class Action Condemns FDA’s “Reckless” Cover-up of Ranitidine Carcinogen

    Class-action law firm Hagens Berman which filed the first lawsuit regarding Sanofi and Boehringer Ingelheim’s intentionally concealed cancer risks in its popular heartburn medication, Zantac, has issued a fact sheet to set the record straight about what attorneys are calling glaring incompetence and shameful conduct from the FDA to date in connection with Zantac. “The FDA’s response with respect to Zantac, in our opinion, is a public disservice and constitutes reckless behavior for an agency tasked with protecting the people,” said Steve Berman, managing partner of Hagens Berman and attorney leading the case for consumers. “The FDA has become a shell of an agency.

  • New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
    PR Newswire

    New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

    PARIS, Sept. 30, 2019 /PRNewswire/ -- Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and who progressed within 12 months on an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) experienced significantly longer radiographic progression free survival (rPFS) with Jevtana® (cabazitaxel) plus prednisone compared with abiraterone plus prednisone or enzalutamide. Overall survival (OS) with Jevtana was also significantly longer.

  • Sanofi Canada receives Gold-Level Parity Certification
    CNW Group

    Sanofi Canada receives Gold-Level Parity Certification

    LAVAL, QC, Sept. 26, 2019 /CNW Telbec/ - Sanofi Canada is pleased to announce that the company has reached a great milestone: our first Parity Certification from the Women in Governance organization. This certification means that Sanofi Canada has taken its place among notable Canadian companies that strive towards gender parity.

  • PR Newswire

    Happify Health and Sanofi Sign Global Agreement to Bring Prescription Digital Mental Health Therapeutics to Individuals with Multiple Sclerosis

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Happify Health, a global leader in mental health technology, today announced it signed an agreement with global biopharmaceutical company Sanofi (SNY) to advance the application of digital therapeutics to address key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety. Happify Health will develop a version of its digital platform specifically for people with MS and plans to submit the co-developed digital therapy to the U.S. Food and Drug Administration for clearance as a medical device. "We've been preparing for our entry into prescription digital therapeutics for several years," said Ofer Leidner, co-founder and president of Happify Health.

  • Sanofi delivered solid growth in Q2 2019
    PR Newswire

    Sanofi delivered solid growth in Q2 2019

    PARIS , July 29, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5.9% +4.1% IFRS ...

  • GlobeNewswire

    Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose

    Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (SNY) to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose (ACO). Opiant intends to reformulate drinabant, a high affinity, selective cannabinoid receptor antagonist, for parenteral administration in an emergency department setting. Opiant licensed exclusive global rights from Sanofi for the development and commercialization of drinabant for the emergency treatment of ACO.

  • PR Newswire

    FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

    PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease.

  • CNW Group

    Canadian employers underestimate the presence of chronic disease in the workforce

    TORONTO , June 11, 2019 /CNW Telbec/ - The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.

  • PR Newswire

    Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019

    - Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma - Longer-term Libtayo® ...

  • Sanofi Recognized by DiversityInc as a Top 50 Company
    PR Newswire

    Sanofi Recognized by DiversityInc as a Top 50 Company

    BRIDGEWATER, N.J., May 8, 2019 /PRNewswire/ -- For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes the nation's top companies for diversity and inclusion management. Sanofi has also been named to two of DiversityInc's Specialty Lists – Top Companies for LGBT Employees and Top Companies for Philanthropy.

  • PR Newswire

    Sanofi Announces Licensing of Dupixent® ▼ (dupilumab) in the EU for the Treatment of Severe Asthma With Type 2 Inflammation

    GUILDFORD, England , May 8, 2019 /PRNewswire/ -- FOR UK MEDIA ONLY  The first biologic licensed in the EU for severe asthma with type 2 inflammation, as characterised by raised blood eosinophils and/or ...

  • PR Newswire

    FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

    BRIDGEWATER, N.J., May 1, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection. Dengvaxia is the first and only vaccine approved for protection against dengue in endemic areas of the U.S. "Dengue is endemic and prone to outbreaks in several U.S. territories, including Puerto Rico, the U.S. Virgin Islands and American Samoa.

  • GlobeNewswire

    Sanofi: Annual General Meeting of April 30, 2019

      Press Release   Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)                                                                                                                                                               ...